This is Stock's Next Target Price...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Both companies have a dominant position in their industry and a solid financial position, but Eli Lilly seems too pricey right now. In contrast, Novo Nordisk seems rather cheap given. The ...
That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...